Kornimate/medical-research-clean huggingface dataset:
alpha-blocker plus diuretic combination therapy as second-line treatment for nocturia in men

Conditions: Nocturia

Summary: the aim of the present study was to determine whether the combined administration of a diuretic agent, hydrochlorothiazide, at night would improve the frequency of nocturia unresponsive to alpha-blocker monotherapy in men with luts.

because nocturia may result in sleep disturbances, daytime fatigue, a lower level of general well-being, and an increased risk of falling at night, it is among the most bothersome of the lower urinary tract symptoms (luts). nocturia is related to a variety of conditions such as aging, overactive bladder (oab), benign prostatic hyperplasia (bph)/luts, medications, diabetes mellitus, diabetes insipidus, anorexia nervosa, and sleep disturbance. in a previous study, we suggested that treatment with terazosin can reduce episodes of nocturia, both subjectively and objectively, in some men with luts. other study showed that in men with nocturnal polyuria, furosemide resulted in a significant reduction in night-time frequency and percentage of the voided volume.

Eligibility criteria:
inclusion criteria: * no response or \< 25% reduction in subjective nocturia by the ipss question 7 after 4-weeks of treatment with terazosin * no response or \< 25% reduction in objective nocturia by the fvc after 4-weeks of treatment with terazosin * nocturia on average two times or more per night (according to the fvc) after 4-weeks of terazosin therapy exclusion criteria: * use of medications for the control of bladder symptoms * use of sedatives or tranquillisers for treating sleep disturbances * bladder tumours * bladder stones * urethral strictures * neurogenic bladder dysfunction * restricted mobility * working primarily at night * a documented history or clinical symptoms of prostatitis, prostate cancer, or prostatic intraepithelial neoplasia on biopsy * serum psa levels of \>20 ng/ml * a history of prostate surgery or radiotherapy, acute urinary retention or an indwelling catheter * evidence of acute urinary infection (pyuria and bacteriuria)on urine analysis

Keywords: nocturia bladder urination disorders hydrochlorothiazide terazosin
french one day survey in 2011 - knowing our population of labile blood products recipients

Conditions: Blood Product Transfusion for All Conditions; Trauma; Surgical Blood Loss; Hematologic Diseases

Summary: describe the epidemiologic profile and clinical context of transfusion recipients in france. describe the clinical context of transfusion. describe the characteristics of the transfusion prescriptions, the use of blood products and the main indications for transfusion. describe transfusion practice according the type of hospital stay.


Eligibility criteria:
inclusion criteria: • transfusion with at least one blood product on the day of the study. exclusion criteria: * none
ibrutinib plus venetoclax in subjects with treatment-naive chronic lymphocytic leukemia /small lymphocytic lymphoma (cll/sll)

Conditions: Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Summary: this is a multicenter, 2-cohort phase 2 study assessing both minimal residual disease (mrd)-guided discontinuation and fixed duration therapy with the combination of ibrutinib + venetoclax in subjects with treatment-naïve cll or sll.


Eligibility criteria:
inclusion criteria: * diagnosis of cll/sll that meets 2008 international workshop on chronic lymphocytic leukemia (iwcll) diagnostic criteria (hallek et al), with active disease meeting at least 1 iwcll criteria for requiring treatment. * measurable nodal disease by computed tomography (ct) * adequate hepatic, and renal function * adequate hematologic function * absolute neutrophil count \>750/µl * platelet count \>30,000 /μl * hemoglobin \>8.0 g/dl exclusion criteria: * any prior therapy used for treatment of cll/sll * known allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for tumor lysis syndrome (tls)
study on osseospeed™ tx implants in a chinese population

Conditions: Partially Edentulous Jaw

Summary: to investigate the clinical efficacy of osseospeed™ tx implants in a chinese population by evaluation of marginal bone level alteration, implant stability and implant survival in the posterior mandible up to 3 years after loading. hypothesis: early loading of the posterior mandible is a safe and predictable procedure.


Eligibility criteria:
inclusion criteria: 1. provision of informed consent 2. aged 20-75 years at enrolment 3. history of edentulism in the posterior mandible, kennedy classes i or ii, of at least four months. last natural tooth in function is canine or first bicuspid. 4. neighboring tooth to the planned bridge must have natural root. 5. presence of natural teeth, partial prosthesis and/or implants in the opposite jaw in contact with the planned bridge. 6. deemed by the investigator to have adequate bone height and a bone width of minimum 5.5 mm. 7. deemed by the investigator as likely to present an initially stable implant situation exclusion criteria: 1. unlikely to be able to comply with study procedures, as judged by the investigator 2. earlier graft procedures in the study area 3. current need for pre-surgical bone or soft tissue augmentation in the planned implant area. 4. uncontrolled pathologic processes in the oral cavity 5. known or suspected current malignancy 6. history of radiation therapy in the head and neck region 7. history of chemotherapy within 5 years prior to surgery 8. systemic or local disease or condition that could compromise post-operative healing and/or osseointegration 9. uncontrolled diabetes mellitus 10. corticosteroids or any other medication that could influence post-operative healing and/or osseointegration 11. smoking more than 10 cigarettes/day 12. present alcohol and/or drug abuse 13. involvement in the planning and conduct of the study (applies to both astra tech staff and staff at the study site) 14. previous enrolment in the present study. 15. simultaneous participation in another clinical study or participation in a clinical study during the last 6 months. 16. subjects that are unable to give informed consent
cardiac rehabilitation and additional physical training in elderly patients after acute coronary syndrome

Conditions: Frailty Syndrome; Ischaemic Heart Disease

Summary: the aim of this study is to evaluate functional and physical capacity, health-related quality of life and associations with frailty in older patients after ischemic heart disease and interventional treatment with an individualized physical training program in the second phase of cardiac rehabilitation.


Eligibility criteria:
inclusion criteria: * patients after acute coronary syndrome and percutaneous coronary intervention or coronary bypass surgery; * age 65 years and older; * 6-minute walk distance (6-mwd) ≥150 meters; * left ventricular ejection fraction ≥ 40%; * patient's agreement to participate in the study. exclusion criteria: * combined coronary artery bypass grafting and valve surgery; * cardiac devices; * diseases in the musculoskeletal system or other organs complicating physical activity and exercise training; * exercise-limiting comorbidities (primarily orthopedic and neurological conditions that would exclude individuals from participating in cardiac rehabilitation according to study protocol), cognitive or linguistic deficits.

Keywords: frailty cardiac surgery cardiac rehabilitation exercise training resistance training balance training
the effectiveness and safety of fk-506 for the treatment of posner-schlossman syndrome

Conditions: Posner Schlossman Syndrome

Summary: to evaluate the effectiveness and safety of tacrolimus eye drops (fk-506) in the treatment of posner-schlossman syndrome. it is expected to collect 30 patients with pss who are in the ophthalmology department of peking university third hospital. the included pss patients were divided into experimental group and control group using simple randomization method. among them, the experimental group was treated with fk-506 twice a day, and the control group was treated with prednisolone acetate ophthalmic suspension 1% 4 times a day. for all pss patients whose intraocular pressure is higher than 30mmhg, also add brinzolamide eye drops 3 times a day. best corrected visual acuity, goldmann intraocular pressure, anterior section photographs, corneal endothelial cells，corneal confocal microscope, heidelberg retinal nerve analysis, octopus visual field were examined on baseline and 1 week, 2 weeks, 3 weeks, 4 weeks after the treatment.


Eligibility criteria:
inclusion criteria: - clinical diagnosis of pss must be able to communicate with doctor and understand this study exclusion criteria: - fuchs syndrome

Keywords: posner schlossman syndrome fk-506 effectiveness safety
real-world registry assessing the clinical use of the lutonix 035 drug coated balloon catheter

Conditions: Peripheral Arterial Disease; Peripheral Vascular Diseases; Arterial Occlusive Diseases

Summary: the objective of this patient registry is to assess the clinical use of the lutonix 035 dcb pta catheter in a heterogeneous patient population in a real world and on-label clinical application.

the registry is a prospective, multicenter, single arm post-market real-world registry in the u.s. assessing the clinical use, safety and outcomes of the lutonix 035 dcb catheter in the superficial femoral artery (sfa) and popliteal arteries (pa). registry subjects will be followed for up to three year's post-index procedure.

Eligibility criteria:
inclusion criteria: 1. the subject provides written informed consent using an informed consent form (icf) that is reviewed and approved by the institutional review board (irb) for the site. 2. the subject agrees to comply with the protocol-mandated follow-up procedures and visits. 3. the subject is ≥ 21 years old. 4. the subject must have a lesion(s) that can be treated with available lutonix 035 dcb catheter according to ifu. exclusion criteria: 1. the subject is unable or unwilling to provide informed consent. 2. the subject is unable or unwilling to comply with the patient registry protocol follow-up procedures and visits. 3. the subject has another medical condition or is currently participating in an investigational drug or an investigational device study that, which, in the opinion of the investigator, may cause him/her to be non-compliant with the protocol, confounds the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of patient registry procedures and follow-up.
a comparative study with parenteral oxycodone, morphine and dexamethasone in postoperative pain in paediatric patients

Conditions: Post Tonsillectomy Pain

Summary: the aim of this randomized, double-blind study is to compare parenteral pre-emptive oxycodone, morphine and dexamethasone with placebo in the treatment of postoperative pain in paediatric patients 4 to 12 years of age. the investigators hope to find out whether there are any differences in postoperative pain and/or adverse effects among these groups.

after the induction of anaesthesia and before intubation the child receives one of the research drugs in a double-blind fashion: 0.1 mg/kg of oxycodone , 0.1 mg/kg of morphine, 0.5 mg/kg dexamethasone (max 24 mg), or placebo. all the research drugs are diluted into a dose of 10 ml with nacl 0.9%, the placebo being solely the dilute. the patients are followed minimum 4h postoperatively: first in the recovery room, and after the patient is stable enough the study is continued in the day-patient unit. level of pain and adverse effects are registered all on same predetermined intervals being 15 min during the first postoperative hour, followed by interval of 30 min until the discharge. the safety measurements noted include pulse, respiratory rate, non-invasive blood pressure and peripheral oxygen saturation are recorded on the same intervals the registering of pain, adverse effects and given medication continues at home for 48 hours post operatively with a questionnaire filled by the parents.

Eligibility criteria:
inclusion criteria: * 4 to 12 years of age * scheduled to tonsillectomy * asa class i or ii * written informed consent is obtained from the parents and the child (when appropriate). exclusion criteria: * allergy to morphine, oxycodone or dexamethasone

Keywords: tonsillectomy paediatric pain child opiates pre-emptive oxycodone morphine dexamethasone
resistance exercise and knee osteoarthritis pain, functional impairment and cartilage turnover

Conditions: Knee Osteoarthritis

Summary: the purpose of this study is to determine if a 4 month resistance exercise program can reduce knee osteoarthritis pain functional impairment and cartilage turnover.


Eligibility criteria:
inclusion criteria: * osteoarthritis (oa) of the knee for \>6 months * moderate to severe pain immediately following a 50-foot walk * knee pain primarily due to tibiofemoral oa and not from patellofemoral oa * bilateral standing anterior-posterior radiograph demonstrating grade 2 or 3 oa of the target knee * willing and able to participate in regular exercise for four months * free from musculoskeletal limitations that would preclude resistance exercise participation * free of abnormal cardiovascular responses during the screening graded maximal walk test exclusion criteria: * unable to walk * regular resistance exercise training (\>3x week) within the past 6 months * specific low back pain or acute back injury * spinal stenosis that precludes walking one block due to neurogenic claudication * any major injury to either knee within the prior 12 months * any surgery to either knee within the last 12 months * lumbar radiculopathy * vascular claudication * significant anterior knee pain due to diagnosed isolated patella-femoral syndrome or chondromalacia in either knee * have had corticosteroid or viscosupplement injections within three months of study participation * have added new over the counter or prescription pain medication within two months of study participation

Keywords: knee osteoarthritis pain function impairment
nuyou:mhealth intervention to preserve and promote ideal cardiovascular health

Conditions: Cardiovascular Disease

Summary: the purpose of the study is to investigate the preservation or promotion of health in students during the college years.

freshman college students at northwestern university will be cluster randomized to two groups based on their dorm. the intervention for one group will target smoking, physical activity, bmi and consumption of fruits and vegetables. the intervention in the second group will target traveling behavior, sexual risk behaviors, sunscreen use and hydration. baseline health and lifestyle measures will be assessed for each participant prior to intervention. health assessments will measure height, weight, fasting glucose, total cholesterol and carbon monoxide. the lifestyle measure will ask questions about physical activity, diet, alcohol and tobacco use, safe sex practices, driving habits, and sunscreen use. these same measures will be repeated during the fall of the students' sophomore and junior years. participants will be given a mobile application and encouraged to track some behaviors. in addition, participants will be asked to answer weekly questions regarding health behaviors.

Eligibility criteria:
inclusion criteria: * freshman at northwestern university in the fall of 2015 * live on campus * read, write and speak english * own an iphone or android smart phone exclusion criteria: * pregnant or trying to become pregnant * established cardiovascular disease * unstable psychiatric or medical condition

Keywords: mobile health smartphone cardiovascular health college students smoking physical activity diet bmi blood pressure cholesterol glucose text facebook instagram push notifications ecological momentary assessment
comparison of 1 versus 2 days post-operative catheterization after anterior colporrhaphy

Conditions: Catheter Related Complication; Anterior Vaginal Wall Prolapse

Summary: patients who undergo anterior vaginal wall plastic surgery and place the bladder catheter during surgery are selected. the purpose of the study is to evaluate the presence of statistically significant differences in bladder catheter repositioning within 12 hours after bladder catheter removal in the group of patients in whom the bladder catheter is removed on postoperative day i or ii. secondary outcomes include evaluation of the incidence of urinary tract infections, number of hospitalization days and total hospitalization costs for patients undergoing anterior vaginal wall surgery in patients in whom the bladder catheter is removed on postoperative day i or ii.


Eligibility criteria:
inclusion criteria: * women 18 years of age or older * patients who are candidates for cystopexy surgery * patients who have consented to the signing of the informed consent exclusion criteria: * micturition dysfunction with preoperative bladder stagnation \> 200 cc at pessary evaluation * history of recurrent cystitis * positive preoperative urine culture * azotemia \> 40 mg/dl or creatininemia \> 1 mg/dl * not collected signed consent endorsed * diabetes mellitus * contraindications to transurethral bladder catheterization * major protocol violations due to unforeseen intraoperative complications (bladder and/or rectal damage, severe bleeding with need for urinary monitoring)
primary cardiac lymphoma: italian multicenter experience

Conditions: Primary Cardiac Lymphoma

Summary: the rationale of this study is to provide an overview on pcl (primary cardiac lymphoma) in italy, trying to shed light on unknown aspects of the disease and on unanswered questions about its management that could be helpful in clinical practice.

primary cardiac lymphoma (pcl), an extranodal lymphoma involving only the heart (with possible involvement of the pericardium) is a rare entity, accounting for 2% of primary cardiac tumors and 0.5% of extranodal lymphomas. it is more frequent in males; clinical presentation is predominated by cardiac symptoms. the most common histology is diffuse large b cell lymphoma (dlbcl). being dlbcl the most frequent histology, patients are usually treated with r-chop (rituximab - cyclophosphamide, doxorubicin, vincristine and prednisone) or r-chop-like chemoimmunotherapy regimens, with an historically poor outcome, although in the last years survival rates significantly increased. due to the rarity of this condition, isolated case reports and a few reviews have been published so far, that in most cases included a population collected in a wide period of time, heterogeneously managed both in terms of treatments received and follow-up, and who often did not strictly respect the criteria of pcl. indeed, while some aspects of pcl are well-known, especially the ones concerning its clinical presentation, a few topics deserve more in-depth analysis. the rationale of this study is to provide an overview on pcl in italy, trying to shed light on unknown aspects of the disease and on unanswered questions about its management that could be helpful in clinical practice.

Eligibility criteria:
inclusion criteria: * diagnosis of pcl (any histotype) defined as an extranodal lymphoma involving only the heart with possible involvement of the pericardium. * age ≥18 years. * diagnosis histologically confirmed. cytofluorimetry analysis of pericardial fluid showing phenotypic features consistent with a primary cardiac lymphoma is permitted if a biopsy sample is not feasible/available for diagnosis; monoclonality is not accepted as a surrogate for diagnosis. * date of diagnosis: from 1st january 2000 to 31st december 2020. * only patients treated in first-line with chemoimmunotherapy regimens including an anti-cd20 monoclonal antibody are eligible for the study. * signed written informed consent (in case of unreachable subject please see chapter 11.2) exclusion criteria: * secondary cardiac involvement from lymphoma; primary mediastinal lymphoma with pericardial infiltration or other lymphomas with involvement of the pericardium/the heart by contiguity and primary effusion lymphoma are not included in this study. * patients treated with chemotherapy regimens that did not include an anti-cd20 monoclonal antibody as first-line therapy. * refuse to sign a written informed consent

Keywords: pcl
motivational interviewing in the management of non alcoholic fatty liver disease

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: the goal of this study is to assess if motivational counselling works to reduce the weight in participants with non alcoholic fatty liver disease (nafld).

participants with nafld who meet inclusion and exclusion criteria and who give informed written consent, will be randomly assigned to the intervention and control group. randomization will be done by using a random sequence generator with concealed allocation.

Eligibility criteria:
inclusion criteria: * aged 18 years to 60 years * body mass index (bmi) is 25 kg/m\^2 or more * newly diagnosed with nafld based on clinical history, ultrasound scan and laboratory values exclusion criteria: * any medical condition that will significantly alter the weight eg: hypothyroidism, hyperthyroidism, cushing disease * having moderate/severe depressive disorders or psychotic symptoms and or substance use disorders that would reduce their capacity to give consent and engage in motivational interview * who are on drugs which will affect weight or mood/affect (eg: corticosteroids) * pregnancy or expecting to be conceive within the study period * having any health conditions that would impede engagement in physical activities * having any health conditions that would compromise the ability to follow the recommended dietary behaviors * concurrent involvement in another weight loss programme

Keywords: motivational interview randomized controlled trial
ivig treatment for asthmatic patients with igg subclass deficiency

Conditions: Asthma

Summary: immunoglobulin g deficiency subtypes in patients with asthma six months once a month intravenous immunoglobulin (400mg/kg/4weeks) infection in treatment-related effect on reducing the frequency of asthma exacerbations appreciate.

patients registration •it is required to ensure that the patients meet the inclusion criteria for this clinical trial, are free from any items of exclusion criteria, are explained about the participation in the clinical trial along with the informed consent forms. procedure •six months once a month intravenous immunoglobulin (400mg/kg/4weeks)

Eligibility criteria:
inclusion criteria: * the patient from over 16 years to under 75 years * patients diagnosed with asthma over six months ago * immunoglobulin g subtypes who were diagnosed with immune deficiency * more than 2 years upper and lower respiratory tract infections , and asthma exacerbations in this regard. * ① calculated creatinine clearance ≧ 50ml/min * alt and ast \<x 3 times the upper limit of normal * alp \<x 3 times the upper limit of normal * total bilirubin \<x 1.5 times the upper limit of normal exclusion criteria: * within six months of the onset of the experiment who received immunoglobulin therapy * immune globulin for those with a history of hypersensitivity reactions * six months ago, another clinical trial participants. * systemic steroids and immunomodulators, such as asthma control that may affect the resources required drug administration. * pregnant or lactating women.

Keywords: immunoglobulin g deficiency